Companion Animal Arthritis Market Research, 2031
The global companion animal arthritis market size was valued at $2.9 billion in 2021, and is projected to reach $5.5 billion by 2031, growing at a CAGR of 7% from 2022 to 2031. Arthritis is a common condition among the companion animals such as dogs and cats which occurs when the cartilage within a joint becomes damaged. If this condition is undiagnosed, the arthritic joint becomes inflamed and painful. Arthritis causes limping, lameness, and stiffness due to loss of muscle mass over the limbs. Weight management is extremely important in companion animals as excess weight on the damaged joint is painful that can expedite the process of cartilage breakdown.
The increase in the population of the companion animals such as dogs, cats, and horses as well as an increase in the prevalence of arthritis among these animals drive the companion animal arthritis market size growth during the forecast period. The companion animal not only provides love and affection to human beings but also helps in reducing stress and related disorders. The growing demand for companion animal care owing to the rise in the number of parasites and infectious diseases is estimated to boost the companion animal arthritis market growth during the forecast period.
Lack of good veterinary care in certain countries is estimated to hamper the growth of companion animal arthritis market opportunity. For instance, restricted access or closure of veterinary services owing to lockdowns imposed across several countries have negatively impacted the market growth during the COVID-19 pandemic. Also, changes in distribution channels caused due to the pandemic with an increase in focus on online shopping owing to the closure of over-the-counter and retail shops are expected to hamper the market growth.
An increase in the population of pet dogs along with supportive awareness programs regarding their health is estimated to generate excellent opportunities in the companion animal arthritis market. As per the analysis, an estimated 20% of the canine population develop osteoarthritis which is equal to 15 million dogs in the U.S. itself. For instance, as per Pet Food Manufacturers Association 2021, the estimated canine population in the UK was around 12.5 million which indicates that a significant number of the dog population is affected by osteoarthritis. In addition, the Centers for Disease Control and Prevention (CDC) conducts various awareness programs that focus on the use of protective joint supplements to keep pets’ joints healthy, maintain their diet, and various exercises to prevent the development of osteoarthritis in the companion animal population.
The key players profiled in this report include Zoetis, Virbac, Elanco, Boehringer Ingelheim International GmbH, Ceva, Dechra Pharmaceuticals PLC., Vetoquinol, NexGen Pharmaceuticals, and Norbrook.
The companion animal arthritis market forecast is segmented on the basis of companion type, arthritis type, treatment, distribution channel, and region. By companion type, the market is divided into dog, cat, and horse. By arthritis type, the market is classified into osteoarthritis and rheumatoid arthritis. By treatment, the market is divided into exercise, medical, and others. By distribution channel, the market is classified into online store, pet supply store, veterinary hospitals and clinics, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The companion animal arthritis market is segmented into Companion Type, Arthritis Type, Treatment and Distribution Channel.
By companion type, the dog segment dominated the market in 2021, owing to the high prevalence of osteoarthritis among dog species that causes lameness, pain, and morbidity in dogs. In addition, an increase in the adoption of dogs globally, as they help in stress management because even small acts such as cuddling them, picking them up, and playing with them can help dog owners in staying happy. This factor is anticipated to drive the growth of the segment in the upcoming years.
By arthritis type, the osteoarthritis segment dominated the global companion animal arthritis market in 2021. Osteoarthritis, also known as Degenerative Joint Disease (DJD), is a progressive joint inflammation caused by cartilage degeneration. Cartilage functions as a cushion in a healthy joint, allowing the joint to move smoothly across its entire range of motion. This cartilage cushion begins to break down in cases of osteoarthritis due to various reasons, such as age, injury, repeated stress, or illness. When this protective cushion is lost, it causes discomfort, inflammation, restricted range of motion, and formation of bone spurs. While osteoarthritis may affect every joint in the body, it usually affects the limbs and lower spine. All these factors are anticipated to boost the growth of this segment.
By treatment, the medical segment dominated the global companion animal arthritis market in 2021. The medical segment comprises various joint supplements and pain management which include Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) that are used as pain relievers for osteoarthritis. NSAIDs not only relieve pain but also reduce joint inflammation. However, long-term use of NSAIDs can have serious adverse effects, especially in people with impaired liver or renal function. These factors are estimated to drive the demand for the medical segment of the companion animal arthritis market.
By distribution channel, the pet supply store segment dominated the global companion animal arthritis market in 2021. Pet supply stores are popular as they offer a variety of pet products including accessories, food items, munchies, as well as medical & health supplements. Pet stores are popular distribution channels for pet owners owing to the availability of a wide range of products, lower costs, and convenience offered by these stores. These stores offer special promotions and vouchers on different products along with supported samples. These factors are anticipated to drive the growth of the pet supply store segment during the forecast period.
By region, North America dominated the global market in 2021 and is projected to remain the fastest-growing segment during the forecast period. The companion animal arthritis demand in countries, namely the U.S. and Canada, is increasing significantly owing to the rise in the pet population due to the growing adoption of dogs and cats. Ease of availability and access to treatments owing to advancements in veterinary treatment facilities is driving the companion animal arthritis market share in this region. As per the U.S. pet ownership statistics for 2017-2018, the percentage of households owning companion animals namely dogs, cats, birds, and horses was 38.4%, 25.4%, 2.8%, and 0.7% respectively. Such an increase in the rate of adoption is driving the growth of the North America companion animal arthritis market.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the companion animal arthritis market analysis from 2021 to 2031 to identify the prevailing companion animal arthritis market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the companion animal arthritis market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global companion animal arthritis market trends, key players, market segments, application areas, and market growth strategies.
Impact of COVID-19 on the Global Companion Animal Arthritis Industry
- COVID-19 negatively impacted various industries, including companion animal arthritis. The companion animal industry faced barriers and challenges during the pandemic, owing to a significant reduction in sales, marketing activities, and awareness regarding companion animal arthritis products. Also, low veterinary clinic admission, cancellation of routine pet check-ups, and a low number of arthritis surgeries performed in veterinary hospitals
- The lockdown imposed across several countries has resulted in limited access and the shutdown of veterinary institutions. The pandemic has made it more difficult for pet owners to acquire sufficient veterinary treatment and care which in turn has reduced veterinarian appointments.
- Economic slowdown affected the setup of new companion animal arthritis treatment facilities across the globe as the majority of government funding was diverted toward the healthcare sector, owing to the rapid spread of the COVID-19 virus, impacting the market to the great extent
- However, governments and veterinary organizations in several countries adopted plans and safety measures to restart veterinary treatment facilities including companion animal arthritis treatment. To mitigate the impact of lockdowns, the American Veterinary Medical Association has recommended necessary safety and precautionary measures to curb the spread of the COVID-19 virus. These safety measures are implemented across veterinary clinics and hospitals.
Companion Animal Arthritis Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 5.5 billion |
 Growth Rate | CAGR of 7% |
 Forecast period | 2021 - 2031 |
 Report Pages | 298 |
 By Companion Type |
|
 By Arthritis Type |
|
 By Treatment |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Boehringer Ingelheim GmbH, Covetrus, Inc., Vetoquinol Animal Health Pvt Ltd, Ceva Sante Animale, Virbac, Dechra Pharmaceuticals plc, Elanco, Zoetis, Phibro Animal Health Corp, Bayer AG |
Analyst Review
The rapid FDA approvals for veterinary therapeutic medications to treat arthritis condition in companion animals such as dogs, cats, and horses is driving the growth of the companion animal arthritis market. While veterinary pharmaceuticals for canine arthritis treatment continue to be more popular, veterinary regenerative medicines have emerged as an intriguing field of R&D for generating innovative therapies like stem cell therapy. The high price of treating companion animal arthritis treatment is impeding the market growth. The shortage of healthcare specialists in the treatment of companion animal arthritis, as well as the high cost of therapy and the lengthy medication approval procedure, are limiting the market expansion. Increase in consumer expenditure on veterinarian services and a rise in animal adoption are driving the market growth. The companion animal arthritis market expansion is expected to be driven by rapid developments in the veterinary healthcare infrastructure across the world.
Based on regional analysis, North America is expected to account for the highest revenue in the market by the end of 2031, followed by Europe, Asia-Pacific, and LAMEA. An increase in the number of companion animals owned per household, as well as a rise in veterinary expenditure, are the key factors responsible for the leading position of North America in the global companion animal arthritis market.
The FDA's rapid approval of veterinary regenerative medicine for the treatment of companion animal arthritis is driving the market growth. An increase in awareness about canine health is expected to accelerate the growth rate of the companion animal arthritis market in the future.
In the upcoming years, the market for companion animal arthritis is expected to develop due to the rise in the frequency of canine arthritis, which has been linked to an increase in dog adoption rates.
North America is anticipated to provide more business opportunities for the global companion animal arthritis market in the future.
The global companion animal arthritis market size was valued at $2,875.5 million in 2021 and is projected to reach $5,520.5 million by 2031, growing at a CAGR of 7.0% from 2022 to 2031.
Zoetis, Virbac, Elanco, and Boehringer Ingelheim International GmbH are the major players in the companion animal arthritis market.
Loading Table Of Content...
